跳到正文
原文
ARD 风湿病年鉴· Lend, K., Lampa, J., Padyukov, L., Hetland, M. L., Heiberg, M. S., Nordström, D. C., Nurmohamed, M. T., Rudin, A., Ostergaard, M., Haavardsholm, E. A., Horslev-Petersen, K., Uhlig, T., Sokka-Isler, T., Gudbjornsson, B., Grondal, G., Frazzei, G., Christiaans, J., Wolbink, G., Rispens, T., Twisk, J. W. R., van Vollenhoven, R. F.·· 2024-11-15AI 评分47

NORD-STAR 随机对照试验:RF/ACPA 与共享表位对早期类风湿关节炎初始治疗应答的关联

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

AI 导读

NORD-STAR 随机对照试验纳入 778 例未经治疗的早期类风湿关节炎患者,随机接受 abatacept、certolizumab pegol、tocilizumab 或常规治疗(均联用甲氨蝶呤),分析 RF、ACPA 及共享表位(SE)等标志物与临床应答的关联。

来源:ARD 风湿病年鉴 · ard.bmj.com